Shanghai Henlius Biotech, Inc. Class H (HK:2696) has released an update.
Shanghai Henlius Biotech is set for a significant restructure as Fosun New Medicine proposes a pre-conditional privatization by merging with Henlius, accompanied by a potential delisting. Shareholders of Henlius have the option to choose between a cash payout or securities in newly established entities under Fosun Pharma as part of the transaction. The merger is contingent on certain pre-conditions and conditions being met or waived as stipulated in the detailed merger agreement.
For further insights into HK:2696 stock, check out TipRanks’ Stock Analysis page.